| Nome |
# |
|
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry, file e309db6f-733a-0599-e053-3705fe0a55db
|
1.024
|
|
Reticulation is a Risk Factor of Progressive Subpleural non-Fibrotic Interstitial Lung Abnormalities, file e309db6f-6a4e-0599-e053-3705fe0a55db
|
607
|
|
Digital lung auscultation: Will early diagnosis of fibrotic interstitial lung disease become a reality?, file e309db6e-4fbe-0599-e053-3705fe0a55db
|
299
|
|
Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit., file e309db6e-2984-0599-e053-3705fe0a55db
|
222
|
|
Subclinical interstitial lung abnormalities: Lumping and splitting revisited, file e309db6e-3beb-0599-e053-3705fe0a55db
|
195
|
|
The impact of fixed triple therapy with beclometasone/formoterol/glycopyrronium on health status and adherence in chronic obstructive pulmonary disease (COPD) in an italian context of real life: The TRITRIAL study protocol, file e309db6e-e2db-0599-e053-3705fe0a55db
|
158
|
|
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage, file e309db6e-037d-0599-e053-3705fe0a55db
|
143
|
|
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials, file e309db6e-3253-0599-e053-3705fe0a55db
|
129
|
|
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis, file e309db6e-47a0-0599-e053-3705fe0a55db
|
127
|
|
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): Insights from the INPULSIS® trials, file e309db6e-56aa-0599-e053-3705fe0a55db
|
119
|
|
COVID-19 and interstitial lung disease: Keep them separate, file e309db6e-bd56-0599-e053-3705fe0a55db
|
104
|
|
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society, file e309db6e-96f4-0599-e053-3705fe0a55db
|
99
|
|
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP), file e309db6e-e1ab-0599-e053-3705fe0a55db
|
99
|
|
Reply to Moodley and to Ravaglia et al, file e309db6e-369f-0599-e053-3705fe0a55db
|
87
|
|
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis, file e309db6e-0b4a-0599-e053-3705fe0a55db
|
85
|
|
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue, file e309db6e-bd5e-0599-e053-3705fe0a55db
|
77
|
|
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis, file e309db6f-870e-0599-e053-3705fe0a55db
|
77
|
|
The characterisation of interstitial lung disease multidisciplinary team meetings: A global study, file e309db6e-56ab-0599-e053-3705fe0a55db
|
76
|
|
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: Relationships with disease progression and pulmonary function trends, file e309db6e-de57-0599-e053-3705fe0a55db
|
71
|
|
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life, file e309db6e-9b58-0599-e053-3705fe0a55db
|
64
|
|
Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis, file e309db6e-bd5c-0599-e053-3705fe0a55db
|
62
|
|
Telemedicine-enabled accelerated discharge of patients hospitalized with COVID-19 to isolation in repurposed hotel rooms, file e309db6e-a8e2-0599-e053-3705fe0a55db
|
54
|
|
Current Diagnosis and Management of Hypersensitivity Pneumonitis, file e309db6e-dc1e-0599-e053-3705fe0a55db
|
54
|
|
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data, file e309db6e-bd54-0599-e053-3705fe0a55db
|
53
|
|
Treatment strategies for asthma: Reshaping the concept of asthma management, file e309db6e-8f05-0599-e053-3705fe0a55db
|
49
|
|
Post-COVID-19 global health strategies: the need for an interdisciplinary approach, file e309db6e-de55-0599-e053-3705fe0a55db
|
49
|
|
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't, file e309db6e-bd60-0599-e053-3705fe0a55db
|
44
|
|
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey, file e309db6e-d8fe-0599-e053-3705fe0a55db
|
38
|
|
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19, file e309db6f-6f98-0599-e053-3705fe0a55db
|
37
|
|
Reply to Fenton et al, file e309db6e-8f06-0599-e053-3705fe0a55db
|
35
|
|
Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies, file e309db6e-080c-0599-e053-3705fe0a55db
|
25
|
|
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial, file e309db6e-47a4-0599-e053-3705fe0a55db
|
22
|
|
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study, file e309db6d-f4b6-0599-e053-3705fe0a55db
|
21
|
|
Post-COVID-19 global health strategies: the need for an interdisciplinary approach, file e309db6e-c3d7-0599-e053-3705fe0a55db
|
18
|
|
Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey, file e309db6e-1af7-0599-e053-3705fe0a55db
|
14
|
|
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF), file 2593809b-d3bb-494d-8e48-746f502f1ac1
|
12
|
|
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone, file e309db6e-6c9e-0599-e053-3705fe0a55db
|
11
|
|
Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis, file e309db6e-154c-0599-e053-3705fe0a55db
|
7
|
|
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients, file e309db6e-77b4-0599-e053-3705fe0a55db
|
7
|
|
Malnutrition in COVID-19 survivors: prevalence and risk factors, file 0a039e8b-8eb7-4b50-a316-9b428299c4a8
|
6
|
|
Update in pulmonary fibrosis 2018, file e309db6e-47ab-0599-e053-3705fe0a55db
|
5
|
|
Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study, file e309db6e-6ca0-0599-e053-3705fe0a55db
|
5
|
|
Severe asthma: One disease and multiple definitions, file e309db6f-8b26-0599-e053-3705fe0a55db
|
4
|
|
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD), file 690097ec-69a2-4abc-97f8-ad2872a058fe
|
3
|
|
An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis: An update of the 2011 clinical practice guideline, file e309db6e-9324-0599-e053-3705fe0a55db
|
3
|
|
Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies, file e309db6f-576a-0599-e053-3705fe0a55db
|
3
|
|
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment, file 5f382efc-eca4-4b4a-b8bc-877205a78817
|
2
|
|
The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis, file e309db6e-1552-0599-e053-3705fe0a55db
|
2
|
|
Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy, file e309db6e-1afb-0599-e053-3705fe0a55db
|
2
|
|
Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib, file e309db6e-2247-0599-e053-3705fe0a55db
|
2
|
|
Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis, file e309db6e-552f-0599-e053-3705fe0a55db
|
2
|
|
Post-COVID lung fibrosis: The tsunami that will follow the earthquake, file e309db6e-84c3-0599-e053-3705fe0a55db
|
2
|
|
Residual respiratory impairment after COVID-19 pneumonia, file e309db6f-49c0-0599-e053-3705fe0a55db
|
2
|
|
Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis, file e309db6f-aee1-0599-e053-3705fe0a55db
|
2
|
|
The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis, file 3d173d85-37d8-4b50-9a96-602fb2ef5ff4
|
1
|
|
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis, file 6487eb1b-5201-4fd6-959e-2bb3482dd025
|
1
|
|
Monitoring small airway dysfunction in connective tissue disease-related interstitial lung disease: a retrospective and prospective study, file 8841c933-fa68-4fef-b5f8-2c0fd717e91a
|
1
|
|
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy, file b60aeba9-acfc-4990-8950-ffdb2c7d76d2
|
1
|
|
Ultrasound-guided needle aspiration biopsy of isolated anterior mediastinal masses, file b76dcdba-7f3c-45be-961c-cc83b3d458cd
|
1
|
|
Diagnosis of idiopathic pulmonary fibrosis An Official ATS/ERS/JRS/ALAT Clinical practice guideline, file e309db6e-1734-0599-e053-3705fe0a55db
|
1
|
|
Statin therapy and lung disorders, file e309db6e-1afd-0599-e053-3705fe0a55db
|
1
|
|
Diagnostic likelihood thresholds that define a working diagnosis of idiopathic pulmonary fibrosis, file e309db6e-3250-0599-e053-3705fe0a55db
|
1
|
|
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study, file e309db6e-3259-0599-e053-3705fe0a55db
|
1
|
|
Role of Stenotrophomonas maltophilia isolation in patients with non CF bronchiectasis, file e309db6e-427f-0599-e053-3705fe0a55db
|
1
|
|
The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: Surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory, file e309db6e-448c-0599-e053-3705fe0a55db
|
1
|
|
Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study, file e309db6e-650c-0599-e053-3705fe0a55db
|
1
|
|
Suggestions for lung function testing in the context of COVID-19, file e309db6e-8875-0599-e053-3705fe0a55db
|
1
|
|
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis, file e309db6e-9326-0599-e053-3705fe0a55db
|
1
|
|
Computed tomographic biomarkers in idiopathic pulmonary fibrosis: The future of quantitative analysis, file e309db6e-aab8-0599-e053-3705fe0a55db
|
1
|
|
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, file e309db6e-c03f-0599-e053-3705fe0a55db
|
1
|
|
Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria, file e309db6e-c384-0599-e053-3705fe0a55db
|
1
|
|
Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial, file e309db6e-c55e-0599-e053-3705fe0a55db
|
1
|
|
Bidirectional epithelial-mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis, file e309db6f-03f5-0599-e053-3705fe0a55db
|
1
|
|
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?, file e309db6f-1498-0599-e053-3705fe0a55db
|
1
|
|
Idiopathic pulmonary fibrosis, file e309db6f-3afe-0599-e053-3705fe0a55db
|
1
|
|
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases, file e309db6f-4021-0599-e053-3705fe0a55db
|
1
|
|
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial, file e309db6f-5768-0599-e053-3705fe0a55db
|
1
|
|
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia, file e309db6f-5b82-0599-e053-3705fe0a55db
|
1
|
|
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective, file e309db6f-87c2-0599-e053-3705fe0a55db
|
1
|
|
CC-90001, a c-Jun N-Terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: Design of a phase 2, randomised, placebo-controlled trial, file e309db6f-a565-0599-e053-3705fe0a55db
|
1
|
| Totale |
4.545 |